Japanese Encephalitis - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 38 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Japanese Encephalitis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Japanese Encephalitis - Pipeline Review, H2 2014', provides an overview of the Japanese Encephalitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Japanese Encephalitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Japanese Encephalitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Japanese Encephalitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Japanese Encephalitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Japanese Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Japanese Encephalitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Japanese Encephalitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Japanese Encephalitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Japanese Encephalitis Overview 6
Therapeutics Development 7
Pipeline Products for Japanese Encephalitis - Overview 7
Pipeline Products for Japanese Encephalitis - Comparative Analysis 8
Japanese Encephalitis - Therapeutics under Development by Companies 9
Japanese Encephalitis - Therapeutics under Investigation by Universities/Institutes 10
Japanese Encephalitis - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Japanese Encephalitis - Products under Development by Companies 14
Japanese Encephalitis - Products under Investigation by Universities/Institutes 15
Japanese Encephalitis - Companies Involved in Therapeutics Development 16
Arbovax, Inc. 16
Indian Immunologicals Limited 17
Panacea Biotec Limited 18
Sanofi 19
Vaxine Pty Ltd 20
Japanese Encephalitis - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 23
Drug Profiles 25
Imojeva - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Japanese encephalitis and West Nile encephalitis vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Japanese encephalitis B vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Japanese encephalitis vaccine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Japanese encephalitis vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Japanese encephalitis vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Japanese encephalitis vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Japanese encephalitis vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Japanese Encephalitis - Recent Pipeline Updates 34
Japanese Encephalitis - Dormant Projects 35
Japanese Encephalitis - Discontinued Products 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Tables
Number of Products under Development for Japanese Encephalitis, H2 2014 7
Number of Products under Development for Japanese Encephalitis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Comparative Analysis by Unknown Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Japanese Encephalitis - Pipeline by Arbovax, Inc., H2 2014 16
Japanese Encephalitis - Pipeline by Indian Immunologicals Limited, H2 2014 17
Japanese Encephalitis - Pipeline by Panacea Biotec Limited, H2 2014 18
Japanese Encephalitis - Pipeline by Sanofi, H2 2014 19
Japanese Encephalitis - Pipeline by Vaxine Pty Ltd, H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 22
Number of Products by Stage and Molecule Type, H2 2014 24
Japanese Encephalitis Therapeutics - Recent Pipeline Updates, H2 2014 34
Japanese Encephalitis - Dormant Projects, H2 2014 35
Japanese Encephalitis - Discontinued Products, H2 2014 36